propranolol + paclitaxel + carboplatin

Cohort A refers to a specific combination therapeutic regimen being evaluated in the Phase II clinical trial NCT07125391 for the treatment of advanced high-grade serous ovarian cancer. This regimen consists of the non-selective beta-adrenergic blocker propranolol hydrochloride administered alongside standard-of-care neoadjuvant chemotherapy, which includes paclitaxel (or its liposomal formulation) and carboplatin. The study, led by Bai-Rong Xia at Anhui Provincial Cancer Hospital, investigates the potential of propranolol to enhance the efficacy of chemotherapy by blocking stress-related adrenergic signaling (specifically via β1 and β2 receptors). Adrenergic signaling is thought to promote tumor progression, angiogenesis, and immune evasion in the tumor microenvironment. Patients in this cohort receive oral propranolol starting one week prior to chemotherapy and continuing through 3–4 cycles of neoadjuvant treatment before undergoing interval debulking surgery (IDS).

Other names

Cohort A-Bai-Rong Xia-ovarian cancer (high-grade serous)Propranolol with Neoadjuvant ChemotherapyPropranolol Hydrochloride + Paclitaxel + Carboplatin